InvestorsKey FinancialsFinancials

Financials

Please find below an overview of recent key financials.

EUR Million	H2 11	H1 11	H2 10	H1 10	H2 09	H1 09	H2 08	H1 08
Revenues	1,735	1,619	1,703	1,605	1,705	1,720	1,766	1,608
Cost of sales	565	543	570	547	621	605	628	574
Gross profit	1,170	1,076	1,133	1,058	1,084	1,115	1,138	1,034

Sales costs	327	304	320	299	296	330	330	308
G&A operating expenses	527	491	466	461	478	493	469	438
Amortization of publishing rights and impairments	86	75	75	72	277	91	68	56
Total operating expenses	940	870	861	832	1,051	914	867	802

Operating profit	230	206	272	226	33	201	271	232

Income from investments	6	0	3	5	0	0	0	0
Financing results	-65	-59	-67	-70	-62	-57	-70	-49
Results on disposals	-5	-3	-4	4	-4	0	1	2
Share of profit of associates	0	0	1	0	2	0	1	-2
Profit before tax	166	144	205	165	-31	144	203	183

Income tax expense	-95	27	-40	-34	8	-11	-32	-39

Profit for the period (loss)	125	117	165	131	-23	133	171	144
Discontinued operations	-16	-108	-4	-5
Total profit for the period	109	9	161	126

Basic EPS (EUR)	0.37	0.03	0.54	0.43	-0.05	0.46	0.59	0.51
Basic EPS from continuing operations (EUR)	0.43	0.39	0.56	0.44
Diluted EPS (EUR)	0.37	0.03	0.54	0.42	-0.05	0.45	0.59	0.50
Diluted EPS from continuing (EUR)	0.42	0.39	0.56	0.43

Ordinary net income	248	196	246	190	224	203	245	178

Ordinary EPS (EUR)	0.84	0.65	0.83	0.64	0.77	0.70	0.86	0.63
Diluted ordinary EPS (EUR)	0.82	0.65	0.82	0.63	0.75	0.70	0.85	0.62
Ordinary Free cash flow	312	131	275	171	278	146	289	106
Figures prior to 2010 reflect unadjusted reported results and include Pharma Solutions